O	0	6	Breast
O	7	13	Cancer
O	14	19	After
O	20	23	Use
O	24	26	of
B-intervention	27	35	Estrogen
I-intervention	36	40	Plus
I-intervention	41	50	Progestin
O	51	54	and
B-control	55	63	Estrogen
I-control	64	69	Alone
O	69	70	:
O	71	79	Analyses
O	80	82	of
O	83	87	Data
O	88	92	From
O	93	94	2
O	95	100	Women
O	100	101	'
O	101	102	s
O	103	109	Health
O	110	120	Initiative
O	121	131	Randomized
O	132	140	Clinical
O	141	147	Trials
O	147	148	.

O	149	152	The
O	153	156	use
O	157	159	of
O	160	170	menopausal
O	171	178	hormone
O	179	186	therapy
O	187	188	(
O	188	190	HT
O	190	191	)
O	192	201	continues
O	202	204	in
O	205	213	clinical
O	214	222	practice
O	222	223	,
O	224	227	but
O	228	235	reports
O	236	239	are
O	240	251	conflicting
O	252	262	concerning
O	263	266	the
O	267	273	longer
O	273	274	-
O	274	278	term
O	279	285	breast
O	286	292	cancer
O	293	300	effects
O	301	303	of
O	304	314	relatively
O	315	320	short
O	320	321	-
O	321	325	term
O	326	329	use
O	329	330	.

O	331	333	To
O	334	340	report
O	341	344	the
O	345	351	longer
O	351	352	-
O	352	356	term
O	357	366	influence
O	367	369	of
O	370	380	menopausal
O	381	383	HT
O	384	386	on
O	387	393	breast
O	394	400	cancer
O	401	410	incidence
O	411	413	in
O	414	417	the
O	418	419	2
O	420	425	Women
O	425	426	'
O	426	427	s
O	428	434	Health
O	435	445	Initiative
O	446	447	(
O	447	450	WHI
O	450	451	)
O	452	462	randomized
O	463	471	clinical
O	472	478	trials
O	478	479	.

O	480	481	A
O	482	487	total
O	488	490	of
B-total-participants	491	493	27
I-total-participants	493	494	,
I-total-participants	494	497	347
B-eligibility	498	512	postmenopausal
I-eligibility	513	518	women
O	519	523	aged
B-age	524	526	50
I-age	527	529	to
I-age	530	532	79
I-age	533	538	years
O	539	543	were
O	544	552	enrolled
O	553	555	at
O	556	558	40
B-location	559	561	US
O	562	569	centers
O	570	574	from
O	575	579	1993
O	580	582	to
O	583	587	1998
O	588	591	and
O	592	600	followed
O	601	603	up
O	604	607	for
O	608	609	a
O	610	616	median
O	617	619	of
O	620	622	13
O	623	628	years
O	629	636	through
O	637	646	September
O	647	651	2010
O	651	652	.

O	653	654	A
O	655	660	total
O	661	663	of
B-total-participants	664	666	16
I-total-participants	666	667	,
I-total-participants	667	670	608
O	671	676	women
O	677	681	with
O	682	683	a
O	684	690	uterus
O	691	695	were
O	696	706	randomized
O	707	709	to
O	710	720	conjugated
O	721	727	equine
O	728	737	estrogens
O	738	739	(
O	739	740	0
O	740	741	.
O	741	744	625
O	745	747	mg
O	747	748	/
O	748	749	d
O	750	751	[
O	751	759	estrogen
O	759	760	]
O	760	761	)
O	762	766	plus
O	767	786	medroxyprogesterone
O	787	794	acetate
O	795	796	(
O	796	797	2
O	797	798	.
O	798	799	5
O	800	802	mg
O	802	803	/
O	803	804	d
O	805	806	[
O	806	815	progestin
O	815	816	]
O	816	817	)
O	818	819	(
O	819	820	E
O	821	822	+
O	823	824	P
O	824	825	)
O	826	828	or
B-control	829	836	placebo
O	837	841	with
O	842	843	a
O	844	850	median
O	851	863	intervention
O	864	872	duration
O	873	875	of
O	876	877	5
O	877	878	.
O	878	879	6
O	880	885	years
O	885	886	,
O	887	890	and
B-total-participants	891	893	10
I-total-participants	893	894	,
I-total-participants	894	897	739
O	898	903	women
O	904	908	with
O	909	914	prior
O	915	927	hysterectomy
O	928	932	were
O	933	943	randomized
O	944	946	to
O	947	957	conjugated
O	958	964	equine
O	965	974	estrogens
O	975	980	alone
O	981	982	(
O	982	983	0
O	983	984	.
O	984	987	625
O	988	990	mg
O	990	991	/
O	991	992	d
O	992	993	)
O	994	996	or
O	997	1004	placebo
O	1005	1009	with
O	1010	1011	a
O	1012	1018	median
O	1019	1031	intervention
O	1032	1040	duration
O	1041	1043	of
O	1044	1045	7
O	1045	1046	.
O	1046	1047	2
O	1048	1053	years
O	1053	1054	.

O	1055	1059	Time
O	1059	1060	-
O	1060	1068	specific
O	1069	1077	invasive
O	1078	1084	breast
O	1085	1091	cancer
O	1092	1101	incidence
O	1102	1107	rates
O	1108	1111	and
O	1112	1123	exploratory
O	1124	1132	analyses
O	1133	1135	of
O	1136	1142	breast
O	1143	1149	cancer
O	1150	1165	characteristics
O	1166	1168	by
O	1169	1181	intervention
O	1182	1185	and
O	1186	1202	postintervention
O	1203	1209	phases
O	1210	1212	in
O	1213	1216	the
O	1217	1218	2
O	1219	1221	HT
O	1222	1228	trials
O	1228	1229	.

O	1230	1232	In
O	1233	1236	the
O	1237	1238	E
O	1239	1240	+
O	1241	1242	P
O	1243	1248	trial
O	1248	1249	,
O	1250	1256	hazard
O	1257	1263	ratios
O	1264	1265	(
O	1265	1268	HRs
O	1268	1269	)
O	1270	1273	for
O	1274	1277	the
O	1278	1287	influence
O	1288	1290	of
O	1291	1299	combined
O	1300	1302	HT
O	1303	1305	on
B-outcome	1306	1312	breast
I-outcome	1313	1319	cancer
O	1320	1324	were
O	1325	1330	lower
O	1331	1335	than
O	1336	1337	1
O	1338	1341	for
O	1342	1343	2
O	1344	1349	years
O	1350	1351	(
O	1351	1353	HR
O	1353	1354	,
O	1355	1356	0
O	1356	1357	.
O	1357	1359	71
O	1359	1360	;
O	1361	1363	95
O	1363	1364	%
O	1365	1367	CI
O	1367	1368	,
O	1369	1370	0
O	1370	1371	.
O	1371	1373	47
O	1373	1374	-
O	1374	1375	1
O	1375	1376	.
O	1376	1378	08
O	1378	1379	)
O	1380	1383	and
O	1384	1392	steadily
O	1393	1402	increased
O	1403	1413	throughout
O	1414	1426	intervention
O	1426	1427	,
O	1428	1436	becoming
O	1437	1450	significantly
O	1451	1460	increased
O	1461	1464	for
O	1465	1468	the
B-outcome	1469	1475	entire
I-outcome	1476	1488	intervention
I-outcome	1489	1494	phase
O	1495	1496	(
O	1496	1498	HR
O	1498	1499	,
O	1500	1501	1
O	1501	1502	.
O	1502	1504	24
O	1504	1505	;
O	1506	1508	95
O	1508	1509	%
O	1510	1512	CI
O	1512	1513	,
O	1514	1515	1
O	1515	1516	.
O	1516	1518	01
O	1518	1519	-
O	1519	1520	1
O	1520	1521	.
O	1521	1523	53
O	1523	1524	)
O	1524	1525	.

O	1526	1528	In
O	1529	1532	the
O	1533	1538	early
O	1539	1555	postintervention
O	1556	1561	phase
O	1562	1563	(
O	1563	1569	within
O	1570	1571	2
O	1571	1572	.
O	1572	1574	75
O	1575	1580	years
O	1581	1585	from
O	1586	1598	intervention
O	1598	1599	)
O	1599	1600	,
O	1601	1606	there
O	1607	1610	was
O	1611	1612	a
O	1613	1618	sharp
O	1619	1627	decrease
O	1628	1630	in
B-outcome	1631	1637	breast
I-outcome	1638	1644	cancer
I-outcome	1645	1654	incidence
O	1655	1657	in
O	1658	1661	the
O	1662	1670	combined
O	1671	1673	HT
O	1674	1679	group
O	1679	1680	,
O	1681	1687	though
O	1688	1691	the
O	1692	1694	HR
O	1695	1703	remained
O	1704	1710	higher
O	1711	1715	than
O	1716	1717	1
O	1718	1719	(
O	1719	1721	HR
O	1721	1722	,
O	1723	1724	1
O	1724	1725	.
O	1725	1727	23
O	1727	1728	;
O	1729	1731	95
O	1731	1732	%
O	1733	1735	CI
O	1735	1736	,
O	1737	1738	0
O	1738	1739	.
O	1739	1741	90
O	1741	1742	-
O	1742	1743	1
O	1743	1744	.
O	1744	1746	70
O	1746	1747	)
O	1747	1748	.

O	1749	1755	During
O	1756	1759	the
O	1760	1764	late
O	1765	1781	postintervention
O	1782	1787	phase
O	1788	1789	(
O	1789	1798	requiring
O	1799	1806	patient
O	1807	1809	re
O	1809	1810	-
O	1810	1817	consent
O	1817	1818	)
O	1818	1819	,
O	1820	1823	the
O	1824	1826	HR
O	1827	1830	for
B-outcome	1831	1837	breast
I-outcome	1838	1844	cancer
I-outcome	1845	1849	risk
O	1850	1858	remained
O	1859	1865	higher
O	1866	1870	than
O	1871	1872	1
O	1873	1880	through
O	1881	1882	5
O	1882	1883	.
O	1883	1884	5
O	1885	1890	years
O	1891	1892	(
O	1892	1898	median
O	1898	1899	)
O	1900	1902	of
O	1903	1913	additional
O	1914	1920	follow
O	1920	1921	-
O	1921	1923	up
O	1924	1925	(
O	1925	1927	HR
O	1927	1928	,
O	1929	1930	1
O	1930	1931	.
O	1931	1933	37
O	1933	1934	;
O	1935	1937	95
O	1937	1938	%
O	1939	1941	CI
O	1941	1942	,
O	1943	1944	1
O	1944	1945	.
O	1945	1947	06
O	1947	1948	-
O	1948	1949	1
O	1949	1950	.
O	1950	1952	77
O	1952	1953	)
O	1953	1954	.

O	1955	1957	In
O	1958	1961	the
O	1962	1970	estrogen
O	1971	1976	alone
O	1977	1982	trial
O	1982	1983	,
O	1984	1987	the
O	1988	1990	HR
O	1991	1994	for
B-outcome	1995	2003	invasive
I-outcome	2004	2010	breast
I-outcome	2011	2017	cancer
I-outcome	2018	2022	risk
O	2023	2026	was
O	2027	2032	lower
O	2033	2037	than
O	2038	2039	1
O	2040	2050	throughout
O	2051	2054	the
O	2055	2067	intervention
O	2068	2073	phase
O	2074	2075	(
O	2075	2077	HR
O	2077	2078	,
O	2079	2080	0
O	2080	2081	.
O	2081	2083	79
O	2083	2084	;
O	2085	2087	95
O	2087	2088	%
O	2089	2091	CI
O	2091	2092	,
O	2093	2094	0
O	2094	2095	.
O	2095	2097	61
O	2097	2098	-
O	2098	2099	1
O	2099	2100	.
O	2100	2102	02
O	2102	2103	)
O	2104	2107	and
O	2108	2116	remained
O	2117	2122	lower
O	2123	2127	than
O	2128	2129	1
O	2130	2132	in
O	2133	2136	the
O	2137	2142	early
O	2143	2159	postintervention
O	2160	2165	phase
O	2166	2167	(
O	2167	2169	HR
O	2169	2170	,
O	2171	2172	0
O	2172	2173	.
O	2173	2175	55
O	2175	2176	;
O	2177	2179	95
O	2179	2180	%
O	2181	2183	CI
O	2183	2184	,
O	2185	2186	0
O	2186	2187	.
O	2187	2189	34
O	2189	2190	-
O	2190	2191	0
O	2191	2192	.
O	2192	2194	89
O	2194	2195	)
O	2195	2196	,
O	2197	2200	but
O	2201	2205	risk
O	2206	2215	reduction
O	2216	2219	was
O	2220	2223	not
O	2224	2232	observed
O	2233	2239	during
O	2240	2243	the
O	2244	2248	late
O	2249	2265	postintervention
O	2266	2272	follow
O	2272	2273	-
O	2273	2275	up
O	2276	2277	(
O	2277	2279	HR
O	2279	2280	,
O	2281	2282	1
O	2282	2283	.
O	2283	2285	17
O	2285	2286	;
O	2287	2289	95
O	2289	2290	%
O	2291	2293	CI
O	2293	2294	,
O	2295	2296	0
O	2296	2297	.
O	2297	2299	73
O	2299	2300	-
O	2300	2301	1
O	2301	2302	.
O	2302	2304	87
O	2304	2305	)
O	2305	2306	.

O	2307	2322	Characteristics
O	2323	2325	of
O	2326	2332	breast
O	2333	2340	cancers
O	2341	2350	diagnosed
O	2351	2357	during
O	2358	2363	early
O	2364	2367	and
O	2368	2372	late
O	2373	2389	postintervention
O	2390	2396	phases
O	2397	2405	differed
O	2406	2408	in
O	2409	2413	both
O	2414	2420	trials
O	2420	2421	.

O	2422	2424	In
O	2425	2428	the
O	2429	2430	E
O	2431	2432	+
O	2433	2434	P
O	2435	2440	trial
O	2440	2441	,
O	2442	2445	the
O	2446	2452	higher
O	2453	2459	breast
O	2460	2466	cancer
O	2467	2471	risk
O	2472	2476	seen
O	2477	2483	during
O	2484	2496	intervention
O	2497	2500	was
O	2501	2509	followed
O	2510	2512	by
O	2513	2514	a
O	2515	2526	substantial
O	2527	2531	drop
O	2532	2534	in
O	2535	2539	risk
O	2540	2542	in
O	2543	2546	the
O	2547	2552	early
O	2553	2569	postintervention
O	2570	2575	phase
O	2575	2576	,
O	2577	2580	but
O	2581	2582	a
O	2583	2589	higher
O	2590	2596	breast
O	2597	2603	cancer
O	2604	2608	risk
O	2609	2617	remained
O	2618	2624	during
O	2625	2628	the
O	2629	2633	late
O	2634	2650	postintervention
O	2651	2657	follow
O	2657	2658	-
O	2658	2660	up
O	2660	2661	.

O	2662	2664	In
O	2665	2668	the
O	2669	2677	estrogen
O	2678	2683	alone
O	2684	2689	trial
O	2689	2690	,
O	2691	2694	the
O	2695	2700	lower
O	2701	2707	breast
O	2708	2714	cancer
O	2715	2719	risk
O	2720	2724	seen
O	2725	2731	during
O	2732	2744	intervention
O	2745	2748	was
O	2749	2758	sustained
O	2759	2761	in
O	2762	2765	the
O	2766	2771	early
O	2772	2788	postintervention
O	2789	2794	phase
O	2795	2798	but
O	2799	2802	was
O	2803	2806	not
O	2807	2814	evident
O	2815	2821	during
O	2822	2825	the
O	2826	2830	late
O	2831	2847	postintervention
O	2848	2854	follow
O	2854	2855	-
O	2855	2857	up
O	2857	2858	.
